40 kDa peginterferon alfa-2a (PEGASYS®) can be administered safely in patients with end-stage renal disease.

被引：0
|
作者：
Lamb, MW
Marks, IM
Wynohradnyk, L
Modi, MW
Preston, RA
Pappas, SC
机构：
[1] Roche Labs Inc, Nutley, NJ USA
[2] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
[3] Univ Miami, Miami, FL 33152 USA
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
618
引用
收藏
页码：326A / 326A
页数：1
相关论文
共 50 条
  • [1] The elderly have a comparable exposure and pharmacodynamics of a branched 40KDA peginterferon alfa-2A (Pegasys™).
    Martin, NE
    Sy, S
    Modi, M
    Ho
    GASTROENTEROLOGY, 2000, 118 (04) : A1466 - A1466
  • [2] Enhanced virological response to treatment with 40 kDa peginterferon alfa-2a (PEGASYS®) in patients previously unresponsive to treatment with interferon alfa-2a.
    Minuk, GY
    Reddy, KR
    Lee, SS
    Heathcote, EJ
    O'Grady, J
    Pockros, PJ
    Shiffman, ML
    Naoumov, NV
    Sedarati, F
    Depamphilis, J
    HEPATOLOGY, 2001, 34 (04) : 330A - 330A
  • [3] Low-dose peginterferon alfa-2a (40kd) (Pegasys®) to treat hepatitis C-infected, end-stage renal disease patients undergoing haemodialysis:: Final study results
    Peck-Radosavljevic, M.
    Boletis, J.
    Besisik, F.
    Ferraz, M. Lucia
    Alric, L.
    Samuel, D.
    Messinger, D.
    Cheinquer, H.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S374 - S374
  • [4] PHARMACOKINETICS (PK) OF RIBAVIRIN (RBV) IN PATIENTS WITH RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE (ESRD) AND CHRONIC HEPATITIS C (CHC) DURING TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) AND RBV (COPEGUS®)
    Wang, Karen
    Lawal, Adebayo A.
    Majchrowicz, Martin
    Morcos, Peter N.
    Moreira, Sebastian
    Draibe, Sergio A.
    Ghalib, Reem H.
    Zaman, Atif
    Crippin, Jeffrey S.
    Joshi, Virendra
    Martin, Paul
    Grippo, Joseph
    HEPATOLOGY, 2008, 48 (04) : 1142A - 1142A
  • [5] Pegylated (40KDA) interferon ALFA-2A (Pegasys™) is unaffected by renal impairment.
    Martin, P
    Mitra, S
    Farrington, K
    Martin, NE
    Modi, MW
    HEPATOLOGY, 2000, 32 (04) : 370A - 370A
  • [6] Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC).
    Ferenci, P
    Shiffman, ML
    Fried, MW
    Sulkowski, MS
    Haeussinger, D
    Zarski, JP
    Goncales, F
    Jensen, DM
    Bonino, F
    Dhumeaux, D
    Blotner, S
    Hoffman, J
    Oliveto, J
    HEPATOLOGY, 2001, 34 (04) : 351A - 351A
  • [7] Rituximab can be safely administered in patients with end-stage renal disease on hemodialysis without dose-modification.
    Gupta, NK
    El-Tarabily, M
    Bedient, S
    Michaels, I
    Gomez, S
    Lee, D
    Stiltner, M
    Bohnen, R
    BLOOD, 2003, 102 (11) : 298B - 298B
  • [8] Can enoxaparin be used safely in end-stage renal disease?
    Dager, William E.
    SEMINARS IN DIALYSIS, 2011, 24 (04) : 381 - 382
  • [9] Long-lasting sustained virological response in chronic hepatitis C patients previously treated with 40 kDa peginterferon alfa-2a (PEGASYS®).
    Swain, M
    Heathcote, EJ
    Lai, MY
    Bain, V
    Feinman, V
    Sherman, M
    Kaita, KD
    Gane, E
    Peltekian, K
    Lindsay, K
    Hoffman, J
    Brunda, M
    HEPATOLOGY, 2001, 34 (04) : 330A - 330A
  • [10] Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease
    Peck-Radosavljevic, Markus
    Boletis, John
    Besisik, Fatih
    Ferraz, Maria Lucia
    Alric, Laurent
    Samuel, Didier
    Messinger, Diethelm
    Tietz, Andreas
    Cheinquer, Hugo
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (03) : 242 - 248
12345